In Reply
Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2016-11, Vol.21 (12), p.e5-e6 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e6 |
|---|---|
| container_issue | 12 |
| container_start_page | e5 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 21 |
| creator | Brandi, Giovanni Deserti, Marzia Vasuri, Francesco Farioli, Andrea Degiovanni, Alessio Palloni, Andrea Frega, Giorgio Barbera, Maria A. de Lorenzo, Stefania Garajova, Ingrid Di Marco, Mariacristina Pinna, Antonio D. Cescon, Matteo Cucchetti, Alessandro Ercolani, Giorgio D’Errico-Grigioni, Antonietta Pantaleo, Maria A. Biasco, Guido Tavolari, Simona |
| description | Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study. |
| doi_str_mv | 10.1634/theoncologist.2016-0286 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5153345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_5153345</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_51533453</originalsourceid><addsrcrecordid>eNqljLsKwjAUQIMotj6-QX8g9ebVx-Iiiq7i4BZijW2kTUpThf69HVycnc6BAwehFYGIxIxvulI7m7vKFcZ3EQUSY6BpPEIhETzDPIPreHBIGU6IyAI08_4JMCijUxTQJIWEAQlRcLLrs26qfoEmD1V5vfxyjraH_WV3xM3rVut7rm3Xqko2ralV20unjPwt1pSycG8piGCMC_b34AOjrkcy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>In Reply</title><source>Oxford Journals Open Access Collection</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Brandi, Giovanni ; Deserti, Marzia ; Vasuri, Francesco ; Farioli, Andrea ; Degiovanni, Alessio ; Palloni, Andrea ; Frega, Giorgio ; Barbera, Maria A. ; de Lorenzo, Stefania ; Garajova, Ingrid ; Di Marco, Mariacristina ; Pinna, Antonio D. ; Cescon, Matteo ; Cucchetti, Alessandro ; Ercolani, Giorgio ; D’Errico-Grigioni, Antonietta ; Pantaleo, Maria A. ; Biasco, Guido ; Tavolari, Simona</creator><creatorcontrib>Brandi, Giovanni ; Deserti, Marzia ; Vasuri, Francesco ; Farioli, Andrea ; Degiovanni, Alessio ; Palloni, Andrea ; Frega, Giorgio ; Barbera, Maria A. ; de Lorenzo, Stefania ; Garajova, Ingrid ; Di Marco, Mariacristina ; Pinna, Antonio D. ; Cescon, Matteo ; Cucchetti, Alessandro ; Ercolani, Giorgio ; D’Errico-Grigioni, Antonietta ; Pantaleo, Maria A. ; Biasco, Guido ; Tavolari, Simona</creatorcontrib><description>Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1634/theoncologist.2016-0286</identifier><identifier>PMID: 27807301</identifier><language>eng</language><publisher>Durham, NC, USA: AlphaMed Press</publisher><subject>Letters to the Editor</subject><ispartof>The oncologist (Dayton, Ohio), 2016-11, Vol.21 (12), p.e5-e6</ispartof><rights>AlphaMed Press 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153345/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153345/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Brandi, Giovanni</creatorcontrib><creatorcontrib>Deserti, Marzia</creatorcontrib><creatorcontrib>Vasuri, Francesco</creatorcontrib><creatorcontrib>Farioli, Andrea</creatorcontrib><creatorcontrib>Degiovanni, Alessio</creatorcontrib><creatorcontrib>Palloni, Andrea</creatorcontrib><creatorcontrib>Frega, Giorgio</creatorcontrib><creatorcontrib>Barbera, Maria A.</creatorcontrib><creatorcontrib>de Lorenzo, Stefania</creatorcontrib><creatorcontrib>Garajova, Ingrid</creatorcontrib><creatorcontrib>Di Marco, Mariacristina</creatorcontrib><creatorcontrib>Pinna, Antonio D.</creatorcontrib><creatorcontrib>Cescon, Matteo</creatorcontrib><creatorcontrib>Cucchetti, Alessandro</creatorcontrib><creatorcontrib>Ercolani, Giorgio</creatorcontrib><creatorcontrib>D’Errico-Grigioni, Antonietta</creatorcontrib><creatorcontrib>Pantaleo, Maria A.</creatorcontrib><creatorcontrib>Biasco, Guido</creatorcontrib><creatorcontrib>Tavolari, Simona</creatorcontrib><title>In Reply</title><title>The oncologist (Dayton, Ohio)</title><description>Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.</description><subject>Letters to the Editor</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqljLsKwjAUQIMotj6-QX8g9ebVx-Iiiq7i4BZijW2kTUpThf69HVycnc6BAwehFYGIxIxvulI7m7vKFcZ3EQUSY6BpPEIhETzDPIPreHBIGU6IyAI08_4JMCijUxTQJIWEAQlRcLLrs26qfoEmD1V5vfxyjraH_WV3xM3rVut7rm3Xqko2ralV20unjPwt1pSycG8piGCMC_b34AOjrkcy</recordid><startdate>20161102</startdate><enddate>20161102</enddate><creator>Brandi, Giovanni</creator><creator>Deserti, Marzia</creator><creator>Vasuri, Francesco</creator><creator>Farioli, Andrea</creator><creator>Degiovanni, Alessio</creator><creator>Palloni, Andrea</creator><creator>Frega, Giorgio</creator><creator>Barbera, Maria A.</creator><creator>de Lorenzo, Stefania</creator><creator>Garajova, Ingrid</creator><creator>Di Marco, Mariacristina</creator><creator>Pinna, Antonio D.</creator><creator>Cescon, Matteo</creator><creator>Cucchetti, Alessandro</creator><creator>Ercolani, Giorgio</creator><creator>D’Errico-Grigioni, Antonietta</creator><creator>Pantaleo, Maria A.</creator><creator>Biasco, Guido</creator><creator>Tavolari, Simona</creator><general>AlphaMed Press</general><scope>5PM</scope></search><sort><creationdate>20161102</creationdate><title>In Reply</title><author>Brandi, Giovanni ; Deserti, Marzia ; Vasuri, Francesco ; Farioli, Andrea ; Degiovanni, Alessio ; Palloni, Andrea ; Frega, Giorgio ; Barbera, Maria A. ; de Lorenzo, Stefania ; Garajova, Ingrid ; Di Marco, Mariacristina ; Pinna, Antonio D. ; Cescon, Matteo ; Cucchetti, Alessandro ; Ercolani, Giorgio ; D’Errico-Grigioni, Antonietta ; Pantaleo, Maria A. ; Biasco, Guido ; Tavolari, Simona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_51533453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Letters to the Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brandi, Giovanni</creatorcontrib><creatorcontrib>Deserti, Marzia</creatorcontrib><creatorcontrib>Vasuri, Francesco</creatorcontrib><creatorcontrib>Farioli, Andrea</creatorcontrib><creatorcontrib>Degiovanni, Alessio</creatorcontrib><creatorcontrib>Palloni, Andrea</creatorcontrib><creatorcontrib>Frega, Giorgio</creatorcontrib><creatorcontrib>Barbera, Maria A.</creatorcontrib><creatorcontrib>de Lorenzo, Stefania</creatorcontrib><creatorcontrib>Garajova, Ingrid</creatorcontrib><creatorcontrib>Di Marco, Mariacristina</creatorcontrib><creatorcontrib>Pinna, Antonio D.</creatorcontrib><creatorcontrib>Cescon, Matteo</creatorcontrib><creatorcontrib>Cucchetti, Alessandro</creatorcontrib><creatorcontrib>Ercolani, Giorgio</creatorcontrib><creatorcontrib>D’Errico-Grigioni, Antonietta</creatorcontrib><creatorcontrib>Pantaleo, Maria A.</creatorcontrib><creatorcontrib>Biasco, Guido</creatorcontrib><creatorcontrib>Tavolari, Simona</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brandi, Giovanni</au><au>Deserti, Marzia</au><au>Vasuri, Francesco</au><au>Farioli, Andrea</au><au>Degiovanni, Alessio</au><au>Palloni, Andrea</au><au>Frega, Giorgio</au><au>Barbera, Maria A.</au><au>de Lorenzo, Stefania</au><au>Garajova, Ingrid</au><au>Di Marco, Mariacristina</au><au>Pinna, Antonio D.</au><au>Cescon, Matteo</au><au>Cucchetti, Alessandro</au><au>Ercolani, Giorgio</au><au>D’Errico-Grigioni, Antonietta</au><au>Pantaleo, Maria A.</au><au>Biasco, Guido</au><au>Tavolari, Simona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Reply</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><date>2016-11-02</date><risdate>2016</risdate><volume>21</volume><issue>12</issue><spage>e5</spage><epage>e6</epage><pages>e5-e6</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.</abstract><cop>Durham, NC, USA</cop><pub>AlphaMed Press</pub><pmid>27807301</pmid><doi>10.1634/theoncologist.2016-0286</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2016-11, Vol.21 (12), p.e5-e6 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5153345 |
| source | Oxford Journals Open Access Collection; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Letters to the Editor |
| title | In Reply |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A42%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Reply&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Brandi,%20Giovanni&rft.date=2016-11-02&rft.volume=21&rft.issue=12&rft.spage=e5&rft.epage=e6&rft.pages=e5-e6&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1634/theoncologist.2016-0286&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_5153345%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27807301&rfr_iscdi=true |